Literature DB >> 10629360

Dementia and antiphospholipid antibodies.

A Mosek1, I Yust, T A Treves, N Vardinon, A D Korczyn, J Chapman.   

Abstract

Antiphospholipid antibodies (aPLAb) may cause both focal ischemic and diffuse brain damage and may be associated with dementia. We have examined the relationship of aPLAb to dementia in the elderly. Blood samples were obtained from 87 consecutive patients with dementia (74 +/- 11 years old) and 69 controls (78 +/- 9 years old), residents of an old age home who were not overtly demented. Levels of aPLAb were measured by a standardized ELISA, utilizing cardiolipin as antigen, and we considered levels above 20 IgG antiphospholipid units (GPLU) as significantly elevated. We found that 5 of the 87 demented patients (6%), but none of the 69 controls, had significantly elevated aPLAb levels (p = 0.03, one-tailed Fisher's exact test). All the patients with high aPLAb levels were diagnosed clinically as having dementia of the Alzheimer type, except for 1 who had mixed dementia, and none had features of an immune-mediated disease. Thus, a small but significant number of patients with dementia have high levels of aPLAb. The role of the aPLAb in these patients, with apparently diffuse brain disease, is currently unknown. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629360     DOI: 10.1159/000017211

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  15 in total

Review 1.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 2.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.

Authors:  Melanie J Harrison; Lisa D Ravdin
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 4.  A patient with bipolar disorder and antiphospholipid syndrome.

Authors:  Jimmy N Avari; Robert C Young
Journal:  J Geriatr Psychiatry Neurol       Date:  2012-03       Impact factor: 2.680

Review 5.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 6.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  Jose F Roldan; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

7.  Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis.

Authors:  Md Asiful Islam; Fahmida Alam; Mohammad Amjad Kamal; Siew Hua Gan; Teguh Haryo Sasongko; Kah Keng Wong
Journal:  Front Aging Neurosci       Date:  2017-08-02       Impact factor: 5.750

8.  Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice.

Authors:  Aviva Katzav; Nikolaos C Grigoriadis; Tania Ebert; Olga Touloumi; Miri Blank; Chaim G Pick; Yehuda Shoenfeld; Joab Chapman
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

9.  Anti-Chol-1 antigen, GQ1bα, antibodies are associated with Alzheimer's disease.

Authors:  Toshio Ariga; Masaru Kubota; Makoto Nakane; Kenji Oguro; Robert K Yu; Susumu Ando
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

Review 10.  Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage.

Authors:  M Carecchio; R Cantello; C Comi
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.